Daily Newsletter

16 October 2023

Daily Newsletter

16 October 2023

PFF Care Center Network expands reach for patients with PF and ILD

The PFF Care Center Network now includes 81 CCN sites and seven Clinical Associates across 39 US states.

October 13 2023

The Pulmonary Fibrosis Foundation (PFF) has expanded its Care Center Network (CCN) with the addition of seven medical centres as Clinical Associate members, a new membership option.

These medical centres will collaborate with existing CCN sites to extend the PFF's resources to individuals living with pulmonary fibrosis (PF) and interstitial lung disease (ILD).

The PFF Care Center Network now includes 81 CCN sites and seven Clinical Associates across 39 US states.

Clinical Associates will work alongside Care Centers to enhance care for PF patients.

They can refer patients for services beyond their capacity and participate in professional development through the CCN.

This expansion aims to improve the quality of care for the more than 250,000 Americans living with PF and ILD, with over 50,000 new cases diagnosed annually.

PFF Care Center Network senior medical adviser Dr. Sonye Danoff said: “With the addition of seven Clinical Associate members, we are actively addressing the critical need to expand access for patients with PF and ILD to the resources available from the PFF, as well as connecting more patients with providers committed to advancing the diagnosis and treatment of PF.

“Our Clinical Associates will extend care to additional people living with these serious conditions and, in collaboration with CCN sites, they will provide patient education, clinical care, and research opportunities, including clinical trials.”

The Pulmonary Fibrosis Foundation aims to accelerate research for new treatments and a cure for PF while offering support and education resources for patients, caregivers, and healthcare providers.

This foundation holds top ratings from Charity Navigator, the Better Business Bureau, and the National Health Council Standards of Excellence Certification Program.

AI will become a key driver of medical device innovation

With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close